in vivo News and Research

RSS

Non-invasive gut health testing breakthrough

Health and functional claims made for foods such as probiotics still need to prove their effectiveness ― an important part of the answer rests in our small intestines and their role in digestion, and immunity.

5 Apr 2013

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration for Humanitarian Use Device designation for its biopolymer scaffolding product.

4 Apr 2013

Polymer scaffolds can advance the development of cancer therapeutics

Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.

3 Apr 2013

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

A team of UC Davis scientists has found that a product resulting from a metabolized omega-3 fatty acid helps combat cancer by cutting off the supply of oxygen and nutrients that fuel tumor growth and spread of the disease.

3 Apr 2013

V/Q imaging can detect early stages of COPD

In vivo ventilation/perfusion (V/Q) imaging can detect early changes to the lung caused by cigarette smoke exposure and provides a noninvasive method for studying lung dysfunction in preclinical models, according to research published in the April issue of The Journal of Nuclear Medicine.

2 Apr 2013

New born neurons as a therapeutic strategy: an interview with Mi-Hyeon Jang, Mayo Clinic in Rochester, Minnesota

There are two regions in the brain that continue to produce new neurons well into adulthood. One of these regions is the hippocampus and as we converse this region is actively involved in memory formation, mood regulation and cognition.

2 Apr 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

Left and right sides of heart develop differently, research shows

Viewed from the outside, our body looks completely symmetrical. However, most internal organs - including the heart - are formed asymmetrically.

27 Mar 2013

Researchers re-programme other cells to become nerve cells, directly in the brain

The field of cell therapy, which aims to form new cells in the body in order to cure disease, has taken another important step in the development towards new treatments.

26 Mar 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.

25 Mar 2013

Researchers study how nerve cells repair themselves after injury

One molecule makes nerve cells grow longer. Another one makes them grow branches. These new experimental manipulations have taken researchers a step closer to understanding how nerve cells are repaired at their farthest reaches after injury.

25 Mar 2013

By charting differing fates of individual T cells, researchers show unpredictable aspects of immune response

By charting the differing fates of individual T cells, researchers have shown that previously unpredictable aspects of the adaptive immune response can be effectively modeled.

21 Mar 2013

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

20 Mar 2013

Illinois chemists use DNA catalysts to do protein's job

Illinois chemists have used DNA to do a protein's job, creating opportunities for DNA to find work in more areas of biology, chemistry and medicine than ever before.

20 Mar 2013

New research project on systems biology of synapse proteins and ageing launched

The AgedBrainSYSBIO project on systems biology of synapse proteins & ageing was officially launched March18th in Paris, France.

20 Mar 2013

Researchers find white blood cells produce and eliminate RBCs

Researchers at Albert Einstein College of Medicine of Yeshiva University and the Icahn School of Medicine at Mount Sinai have found that macrophages - white blood cells that play a key role in the immune response - also help to both produce and eliminate the body's red blood cells (RBCs).

18 Mar 2013

Max Planck Florida Institute for Neuroscience gets grant for research into neurological disorders

The Max Planck Florida Institute for Neuroscience, the first and only U.S. extension of the prestigious Max Planck Society, today announced it has received approximately $1,257,500 in grant funding from prestigious national and international organizations to fund research into Parkinson-s, epilepsy and other neurological disorders.

15 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

Scientists discover key biochemical step underlying heart failure

Some 5.8 million Americans suffer from heart failure, a currently incurable disease. But scientists at Temple University School of Medicine's (TUSM) Center for Translational Medicine have discovered a key biochemical step underlying the condition that could aid the development of new drugs to treat and possibly prevent it.

6 Mar 2013

in vivo News and Research

Non-invasive gut health testing breakthrough

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

Polymer scaffolds can advance the development of cancer therapeutics

UC Davis scientists find mechanism in metabolized omega-3 fatty acid that helps combat cancer

V/Q imaging can detect early stages of COPD

New born neurons as a therapeutic strategy: an interview with Mi-Hyeon Jang, Mayo Clinic in Rochester, Minnesota

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Left and right sides of heart develop differently, research shows

Researchers re-programme other cells to become nerve cells, directly in the brain

arGEN-X advances ARGX-112 into formal preclinical development

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Researchers study how nerve cells repair themselves after injury

By charting differing fates of individual T cells, researchers show unpredictable aspects of immune response

New biodegradable nanoparticles deliver inflammation-resolving drugs to sites of tissue injury

Illinois chemists use DNA catalysts to do protein's job

New research project on systems biology of synapse proteins and ageing launched

Researchers find white blood cells produce and eliminate RBCs

Max Planck Florida Institute for Neuroscience gets grant for research into neurological disorders

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Scientists discover key biochemical step underlying heart failure

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News